Keytruda is an immunotherapy drug that is prescribed to cancer patients and is used to treat different types of cancer. It was first approved by the FDA in 2014 for the treatment of advanced or ...

May 21 () - Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another ‌part ...

Merck stock popped early Friday after European officials recommended approving its combination for a form of bladder cancer.

EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...

Health minister hopes a key injectable cancer drug will be available in all five trusts "as soon as possible".

Merck shares rose after partner Kelun-Biotech reported positive late-stage trial results for a Keytruda combination treatment ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer. Merck has ...

Findings from a phase 2 trial showed improvements in relapse-free survival with an mRNA vaccine plus Keytruda compared with Keytruda alone in patients with high-risk resected melanoma. The combination ...

Moderna and Merck's cancer vaccine, used in combination with Merck's Keytruda, reduced the risk of melanoma spreading to other parts of the body or death by 65% compared with Keytruda alone. Melanoma ...

The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program, as the third Phase 3 trial for the investigational individualized neoantigen therapy, V940 ...

Merck reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products.  The pharmaceutical giant also narrowed its 2026 sales ...

The Department of Health says it is "aware" of the jab and is "exploring" how it can be made available "as soon as possible".